

Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

Supplementary Material

Table S1. Baseline characteristics of population excluded because of missing information

	Control group (n = 739)		Tocilizumab (n = 79)		p
Age, median (IQR)	n=739	69 (54 – 81)	n=79	67 (58 – 75)	0.312
Gender, n (%)					
Male	n=407	407 (55)	n=55	55 (70)	0.013
Female	n=332	332 (45)	n=24	24 (30)	
Past medical history, n (%)					
Hypertension	n=739	133 (18)	n=79	20 (25)	0.120
Diabetes	n=739	199 (27)	n=79	25 (32)	0.391
Congestive heart failure	n=739	31 (4)	n=79	4 (5)	0.727
Coronary artery disease	n=739	50 (7)	n=79	6 (8)	0.794
Chronic kidney disease	n=739	31 (4)	n=79	1 (1)	0.202
Lung disease	n=739	55 (7)	n=79	3 (4)	0.225
Vital signs at admission					
Heart rate (bpm), median (IQR)	n=683	80 (71 – 90)	n=68	82 (72 – 93)	0.563
Systolic blood pressure (mmHg), median (IQR)	n=506	126 (112 – 140)	n=45	120 (110 – 133)	0.049
Temperature (°C), median (IQR)	n=715	36.4 (36 – 37)	n=71	36.6 (36.1 – 37.1)	0.099
Peripheral oxygen saturation (%), median (IQR)	n=378	95 (93 – 97)	n=14	93 (85 – 95)	0.002
Needing supplemental oxygen	n=734	190 (26)	n=79	18 (23)	0.548

Baseline laboratory					
Absolute lymphocyte count (cells/uL), median (IQR)	n=582	110 (790 - 1560)	n=71	890 (700 - 1250)	0.003
Absolute neutrophil count (cells/uL), median (IQR)	n=582	4550 (3060 - 6800)	n=71	6210 (3720 - 10360)	<0.001
LDH (U/L), median (IQR)	n=524	482 (388 - 630)	n=69	628 (489 - 942)	<0.001
ALT (U/L), median (IQR)	n=500	24 (16 - 39)	n=71	30 (20 - 41)	0.037
Urea (mg/dL), median (IQR)	n=519	35 (27 - 51)	n=68	38 (25 - 50)	0.522
C-reactive protein (mg/L), median (IQR)	n=551	54 (18-114)	n=71	120 (40-208)	<0.001
D-dimer (ng/mL), median (IQR)	n=385	636 (370 - 1519)	n=67	784 (525 - 1754)	0.038
Interleukin 6 (pg/mL), median (IQR)	n=6	41 (18 - 193)	n=10	34 (14 - 820)	0.983
Outcome					
Non-ICU length of stay (days), median (IQR)	n=739	7 (4 - 9)	n=79	14 (10 - 19)	<0.001
ICU admission, n (%)	n=739	38 (5)	n=79	28 (35)	<0.001
ICU length of stay (days), median (IQR)	n=38	2 (1 - 3)	n=28	6 (2 - 11)	0.006
Mortality, n (%)	n=739	123 (17)	n=79	28 (35)	<0.001
ICU or mortality, n (%)	n=739	123 (17)	n=79	30 (38)	<0.001

Abbreviations: ALT, alanine aminotransferase; ICU, intensive care unit; IQR, interquartile range; LDH, lactate dehydrogenase.

Table S2. Adjusted hazard ratios for tocilizumab use in marginal structural models.

	C-reactive protein >150 mg/dL							C-reactive protein ≤ 150 mg/dL						
	Mortality				ICU or mortality			Mortality				ICU or mortality		
	No.	aHR	95% CI	p	aHR	95% CI	p	No.	aHR	95% CI	p	aHR	95% CI	p
All	286	0.34	0.16, 0.72	0.005	0.39	0.19, 0.80	0.011	943	1.21	0.65, 2.23	0.552	1.41	0.77, 2.58	0.264
Lymphocyte count < 1000 cells/uL	187	0.24	0.10, 0.57	0.001	0.24	0.10, 0.57	0.001	397	1.20	0.61, 2.37	0.591	1.37	0.69, 2.71	0.361
D-dimer > 1000 ng/mL	147	0.23	0.09, 0.61	0.003	0.23	0.09, 0.61	0.003	282	1.29	0.55, 3.03	0.555	1.35	0.58, 3.13	0.489
Receiving corticosteroids	176	0.39	0.17, 0.90	0.028	0.44	0.20, 0.98	0.046	406	0.86	0.44, 1.65	0.645	1.00	0.43, 1.88	0.995
Receiving hydroxychloroquine	270	0.32	0.13, 0.79	0.015	0.38	0.16, 0.91	0.030	864	1.35	0.69, 2.63	0.373	1.59	0.83, 3.05	0.163
Receiving azithromycin	212	0.39	0.12, 1.22	0.105	0.44	0.16, 1.20	0.108	600	1.07	0.42, 2.70	0.894	1.31	0.54, 3.17	0.550
Receiving lopinavir/ritonavir	199	0.26	0.77, 0.88	0.030	0.34	0.11, 1.13	0.079	554	1.40	0.56, 3.54	0.472	1.75	0.72, 4.27	0.219

Table shows adjusted hazard ratios for tocilizumab versus non-tocilizumab (reference category).

Models adjusted for sex, age, comorbidities (hypertension, diabetes, ischemic heart disease, chronic kidney disease, congestive heart failure, lung disease), need for oxygen therapy at baseline, oxygen blood saturation and time-varying parameters of severity (blood pressure, heart rate, total lymphocyte and neutrophil count, LDH, ALT, urea, D-dimer, and C reactive protein).

Abbreviations: aHR, adjusted hazard ratio; ALT, alanine aminotransferase, CI, confidence interval; LDH, lactate dehydrogenase; No, number of individuals.